Hong Kong Stock Volatility | Yingnuo Pharmaceutical-B surges nearly 28%, with impressive first-year performance and significant commercialization potential of core products

NightAirdropper · 2026-03-25T22:44:47+00:00

Sinnopharm Pharma-B stock price surged nearly 28% in afternoon trading. As of the end of 2025, revenue was approximately 131.5 million yuan, with a gross margin of 89%. The core product isupatagro peptide α has been approved for treating T2D and included in medical insurance coverage. The company will continue to advance R&D and commercialization over the next 3-5 years.

NightAirdropper

2026-03-25 22:44:47

Abstract generation in progress

Gelonghui March 24 | Silver Nuo Pharmaceuticals-B (2591.HK) surged in the afternoon, rising nearly 28% at one point, reaching a high of HKD 25.82.

On the news front, Silver Nuo Pharmaceuticals-B announced its annual results for the year ending December 31, 2025. The group generated approximately RMB 131.5 million in revenue, mainly from the sale of Ispaglucase in China; gross profit was about RMB 117.1 million, with a gross margin of 89%. As of the end of 2025, the company had cash and cash equivalents of RMB 969 million, net assets of RMB 1.053 billion, and an asset-liability ratio of only 33%, with no short-term debt repayment pressure. The ample cash reserves can support 3-5 years of R&D and commercialization investments.

The group’s core product, Ispaglucase, is a humanized long-acting GLP-1 receptor agonist with an ultra-long half-life, good safety, and tolerability. It demonstrates differentiated potential in administration convenience, blood sugar control, and metabolic benefits. During the reporting period, Ispaglucase was approved in China for the treatment of T2D and has been commercialized. The product was also included in the national medical insurance drug list, effective from January 1, 2026. Additionally, the group continues to advance clinical development of Ispaglucase for obesity, overweight, and MASH, while also progressing registration in some overseas markets. (Gelonghui)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.